ESMO 2018 | Durvalumab plus danvatirsen for R/M HNSCC: exciting SCORES data
The SCORES trial (NCT02499328) is investigating the combination of durvalumab plus danvatirsen (a STAT3 pathway inhibitor) or AZD5069 (a CXCR2 inhibitor) for advanced solid tumors and recurrent/metastatic head and neck squamous cell carcinoma. Here, Ezra Cohen, MD, FRCPSC, FASCO, of the UC San Diego Moores Cancer Center, San Diego, CA, discusses the updated results of this trial, including exciting efficacy data. This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.
Get great new content delivered to your inboxSign up